Skip to Content
Merck
CN

47635

Fmoc-Phe-OH

purum, ≥98.0% (HPLC)

Synonym(s):

N-(9-Fluorenylmethoxycarbonyl)-L-phenylalanine, Fmoc-L-phenylalanine

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C24H21NO4
CAS Number:
Molecular Weight:
387.43
EC Number:
252-661-1
UNSPSC Code:
12352200
PubChem Substance ID:
Beilstein/REAXYS Number:
3597808
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

purum

assay

≥98.0% (HPLC)

optical activity

[α]20/D −40±2°, c = 1% in DMF

mp

180-187 °C

storage temp.

2-8°C

SMILES string

OC(=O)[C@H](Cc1ccccc1)NC(=O)OCC2c3ccccc3-c4ccccc24

InChI

1S/C24H21NO4/c26-23(27)22(14-16-8-2-1-3-9-16)25-24(28)29-15-21-19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h1-13,21-22H,14-15H2,(H,25,28)(H,26,27)/t22-/m0/s1

InChI key

SJVFAHZPLIXNDH-QFIPXVFZSA-N



Still not finding the right product?

Explore all of our products under Fmoc-Phe-OH


Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Chiao-Ting Yen et al.
European journal of medicinal chemistry, 44(5), 1933-1940 (2008-12-27)
Twenty-four new dipeptide analogs (1-24) of aurantiamide acetate were designed, synthesized, and assayed for effects on superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB. Among them, seven N-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides (6, 9, 12, 14, 17, 18
Soo Min Cho et al.
Scientific reports, 4, 6777-6777 (2014-10-28)
Amyloid-β (Aβ) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing Aβ levels in the cerebrospinal fluid (CSF) during the development of Alzheimer's disease (AD), the link